Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005

This article has no abstract
Epistemonikos ID: df18b2358397e773f9f0fc73586347f6ca8403fb
First added on: Feb 19, 2025